Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial.

Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial. Abstract Text:

OBJECTIVE: We compared the effect of levomepromazine (LMP) with chlorpromazine (CPZ) in treatment-resistant schizophrenia (TRS). METHODS: We carried out a double-blind, parallel group study (n = 19/arm) with balanced randomization in blocks of 4 and stratification by sex. Subjects entered a 30-week trial, of which phases I-III were open: phase I (wk 0-6) baseline; phase II (wk 7-9) stepwise transition to haloperidol (HAL), 30 mg/d, plus benztropine (BT), 4 mg/d; phase III (wk 10-15) HAL, 40-60 mg/d, plus BT, 4-6 mg/d; phase IV (wk 16-20) stepwise transition to LMP or CPZ (500 mg/d) following randomization; phase V (wk 21-28) stepwise increase of LMP or CPZ (600-1000 mg/d, dose reduction permitted) to establish optimum dose; and phase VI (wk 29-30) optimized dose maintained. Criteria for TRS were based on those established by Kane et al in 1988. The criterion for a response to treatment was a reduction of 25% or more in total Brief Psychiatric Rating Scale score. RESULTS: Both LMP (p = 0.007) and CPZ (p = 0.030) improved TRS relative to baseline. Although there was no significant difference between the 2 groups in treatment response at study end point, hierarchical linear modelling of longitudinal outcome revealed a significant (p = 0.006) advantage of LMP over CPZ for the BPRS total score. Ten of 19 participants on LMP and 8 of 19 on CPZ met the criterion for treatment response, and 9 of the 18 responders did so on 200-700 mg/d phenothiazine. The mean dose of responders was 710 (standard deviation [SD] 265) mg/d (LMP) and 722 (SD 272) mg/d (CPZ). Akathisia was associated with a nonresponse to phenothiazines (p = 0.010). BPRS scores increased significantly on HAL (p = 0.006). Two of 19 participants on LMP and 5 of 19 on CPZ withdrew early from the study. CONCLUSION: LMP and CPZ may be useful in the management of TRS. A modest advantage of LMP compared with CPZ was seen in longitudinal analysis. High doses of neuroleptics may contribute to TRS; reduction of neuroleptics to modest or moderate doses should be considered before categorizing a patient as treatment resistant.

Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial. Publishing Authors By Initials

For similar behavioral disciplines and activities: schizophrenic psychology research abstracts see: behavioral disciplines and activities: schizophrenic psychology research

PUBMED ID PMID:

MEDLINE DATE:

Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Journal of psychiatry & neuroscience : JPN

VOLUME: 31

Page Numbers: 271-9

Journal Abbreviation: J Psychiatry Neurosci

ISSN: 1180-4882

DAY: 6

MONTH: Jul

YEAR: 2006

Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9107859

Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial. Keywords Mesh Terms:

KEYWORDS: Schizophrenic Psychology

MESH TERMS: drug therapy

Chemical & Substance for Abstract: Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial. Information

Substance Name: Methotrimeprazine

Registry Number: 60-99-1

Grant and Affiliation Information for Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial.

AFFILIATION: Douglas Hospital Research Centre, 6875 LaSalle Boulevard, Verdun, Montréal, Quebec. samarthji.lal@muhc.mcgill.ca

Country: Canada

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Psychiatry Neurosci

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial Related Publications

• A dominant-negative p65 PAK peptide inhibits angiogenesis.
• After the war on terrorism, an attack on antibiotic resistance.
• Antiphase oscillation of the left and right suprachiasmatic nuclei.
• Changes in systolic blood pressure associated with lead in blood and bone.
• EDITORIAL: Globalization of Pediatrics.
• EDITORIAL:: Preparing for Future Amazement.
• Editorial.
• Editorial.
• Evaluation of 2 novel approaches for assessing the ability of demineralized freeze-dried bone allograft to induce new bone formation.
• Evidence for a coupling of synthesis and export of an outer membrane protein in Escherichia coli.
• Expression of chick Tbx-2, Tbx-3, and Tbx-5 genes during early heart development: evidence for BMP2 induction of Tbx2.
• In vivo DTI evaluation of white matter tracts in rat spinal cord.
• Integrative capacity of the caudal brainstem in the control of food intake.
• Lipid-lowering pharmacoeconomic studies. Reactor panel and open forum.
• MR Imaging and Epilepsy-3T or not 3T? That Is the Question.
• Monoclonal antibodies reveal lamB antigenic determinants on both faces of the Escherichia coli outer membrane.
• Monoclonal antibody as a probe for structure and function of an Escherichia coli outer membrane protein.
• Mutations that alter the transport function of the LamB protein in Escherichia coli.
• Nonadiabatic molecular dynamics simulations of correlated electrons in solution. 1. Full configuration interaction (CI) excited-state relaxation dynamics of hydrated dielectrons.
• Occupational health in Brazil.
• Phage lambda receptor (lamB protein) in Escherichia coli.
• Potential of porous poly-D,L-lactide-co-glycolide particles as a carrier for recombinant human bone morphogenetic protein-2 during osteoinduction in vivo.
• Recombinant bone morphogenetic protein (BMP)-2 regulates costochondral growth plate chondrocytes and induces expression of BMP-2 and BMP-4 in a cell maturation-dependent manner.
• Reconsidering the early steps of protein secretion.
• Taxotere-induced inhibition of human endothelial cell migration is a result of heat shock protein 90 degradation.
• The ISPOR Lipid Conference: Pharmacoeconomics and Outcomes Modeling Issues.
• The Suprachiasmatic Nucleus is a Functionally Heterogeneous Timekeeping Organ.
• Transition path sampling study of classical rate-promoting vibrations.
• Using Per gene expression to search for photoperiodic oscillators in the hamster suprachiasmatic nucleus.
• p21-activated kinase regulates endothelial permeability through modulation of contractility.